Sitagliptin
- Half-Life (t½)
- PO: 10.4h
- Formula
- C16H15F6N5O
- Molecular Weight
- 407.31 g/mol
- Aliases
- Januvia, MK-0431
Pharmacological Mechanism
Competitive, reversible DPP-4 (dipeptidyl peptidase-4) inhibitor — blocks degradation of the endogenous incretins GLP-1 and GIP, raising their plasma levels 2–3× and potentiating glucose-dependent insulin release plus glucagon suppression. Weight-neutral, low hypoglycaemia risk (glucose-dependent action). CV-neutral (TECOS trial).
Half-Life & Elimination Curve (PO: 10.4h)
Elimination (PO)Effect Site (ke0)
- 0×t½0h100% (0.444 mg/L)
- 1×t½10.4h50% (0.222 mg/L)
- 2×t½20.8h25% (0.111 mg/L)
- 3×t½31.2h12.5% (55.5 µg/L)
- 4×t½41.6h6.3% (27.7 µg/L)
- 5×t½52h3.1% (13.9 µg/L)
Dosing Guidelines
- Oral (PO): Typical 100 mg
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 87% · Volume of Distribution (Vd): 196 L [PMID 17220239]
- Effect-Site Equilibration (ke0): 1 h⁻¹ (equilibration half-time t½ke0 ≈ 42m) [PMID 15634008]
Receptor Binding & Occupancy
Pathways It Modulates
Target Organ Systems
Interactions
- Metformin (synergistic): Standard dual-therapy combination; Janumet combines the two.
- Semaglutide / GLP-1 RAs (caution): Overlapping incretin mechanism — generally not combined (redundant PD + additive GI).
Chemical Structure & Identifiers
- InChIKey: MFFMDFFZMYYVKS-SECBINFHSA-N
- SMILES: C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
References